Globus Medical enters its August 4 earnings window with short sellers rebuilding positions at the fastest pace in months — even as options traders stay decisively bullish and the Street holds broadly constructive targets well above the current price.
The short interest story is the week's most striking datapoint. Bearish positioning has climbed 55% over the past month to 5.8% of free float — roughly 6.4 million shares — with the bulk of that build arriving across late June and early July. The move is notable in context: shorts stood near 4 million shares in late May and have now added the equivalent of roughly half that position in six weeks. The pace of accumulation marks this as a genuine conviction build, not noise. That said, the lending market remains comfortable — availability is running at 617%, meaning there are roughly six shares available to borrow for every one currently lent out. Cost to borrow has risen 24% over the past week to 0.54%, but that absolute level remains low. This is a crowded-shorts story on the positioning side, not a squeeze setup.
Options positioning tells the opposite story. Calls are heavily outpacing puts, with the put/call ratio at 0.19 — more than a full standard deviation below its 20-day average of 0.42 and near the lowest level of the past year. The contrast with short interest is sharp: bears are building through the stock-borrow market, while options traders are loading up on upside exposure. Both camps cannot be right, and the divergence sets up August 4 as a genuine coin toss in terms of directional conviction.
The Street sits broadly bullish but has been trimming targets. Stifel lowered its target to $80 — essentially current price — while maintaining a Hold rating, the most cautious recent action. Piper Sandler, still rated Overweight, cut from $115 to $100 in mid-June. The mean analyst target across the coverage universe is $109, implying roughly 38% upside from the $78.83 close — a significant premium that reflects lingering optimism about the NuVasive integration and Globus's international expansion. Bulls point to consistent earnings growth, a strong product portfolio, and a 23% one-year revenue increase. Bears worry about margin pressure from competitive recruiting, slower adoption in the Enabling Technologies segment, and execution risk as the merger digest continues. The EV/EBITDA multiple has drifted to 9.6x, and the P/E of 16.6x is undemanding relative to peers — but the discount may reflect justified caution rather than a clear value opportunity.
Earnings history adds a cautionary note for longs. The May 2026 print delivered a 12.6% single-day decline, and the five-day move after that release was -13.5%. The prior print in early February saw a milder -1.5% day-one move but a -16% five-day drift. Two consecutive earnings events punished shareholders meaningfully. With short sellers now sitting at a six-week high in position size and a fresh Stifel target cut arriving the morning of July 8 — cutting to $80 from $95 — the setup heading into August 4 looks more charged than usual.
Among peers, AORT gained 9.2% on the week and VREX rose 6.7%, while GMED slipped 0.2% — a quiet week in isolation, but the divergence suggests some sector rotation toward more momentum-driven names. CNMD fell 0.5%, roughly in line with GMED, while PODD added 2.4%. The relative underperformance versus the better-performing peers bears watching as August approaches.
The August 4 print is the obvious next catalyst — the question is whether the short build reflects informed anticipation of another disappointing quarter, or whether the call-heavy options market is pricing a recovery from two consecutive post-earnings drawdowns.
See the live data behind this article on ORTEX.
Open GMED on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
